WW Stock Recent News
WW LATEST HEADLINES
Short-seller Cedar Grove argues that WeightWatchers can't win in a GLP-1 world. The stock has fallen sharply this year after Eli Lilly announced a new telehealth service.
A prognosticator sounded a warning about the weight loss specialist. He noted that competition is increasing, and traditional dieting methods are declining in popularity.
Powerful healthcare company Eli Lilly introduced a new e-commerce platform that will surely boost sales of its new weight loss drug. Investors fear this will put a real dent in WW International's business.
Eli Lilly stock just announced a new online service for obtaining prescriptions and ordering weight loss drugs. WW stock is reacting negatively to the news.
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication and WW International Inc. NYSE: WW (WeightWatchers) principles of nutrition and exercise.
Options bears are blasting WW International (WW) today, with 2,010 puts exchanged so far – double the intraday average volume – compared to just 995 calls. Most active is the January 2024 7.50-strike call, but positions are currently opening at the 9.50-strike put in that series.
WeightWatchers launches a new program dedicated to helping people who have jumped on the weight-loss drug bandwagon. The program is called the GLP-1 Program.
Yahoo Finance's Brooke DiPalma breaks down WW International's nutrition program incorporating popular weight loss drugs and how pharmaceutical stocks are responding.
The weight-loss platform is launching a new plan, the WeightWatchers GLP-1 Program, for those who are obese or overweight and taking any of the increasingly popular injectable drugs that help with curbing hunger, such as Ozempic, Wegovy and Saxenda. Such drugs are known as GLP-1 medications because they mimic a gut hormone known as GLP-1, which can reduce appetite.
If you want to follow Oprah Winfrey's latest plan for losing weight, be prepared to do, well, everything.